Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.

Hopkins S, Bobardt M, Chatterji U, Garcia-Rivera JA, Lim P, Gallay PA.

Antimicrob Agents Chemother. 2012 Jul;56(7):3888-97. doi: 10.1128/AAC.00693-12. Epub 2012 May 14.

2.

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.

Chatterji U, Lim P, Bobardt MD, Wieland S, Cordek DG, Vuagniaux G, Chisari F, Cameron CE, Targett-Adams P, Parkinson T, Gallay PA.

J Hepatol. 2010 Jul;53(1):50-6. doi: 10.1016/j.jhep.2010.01.041. Epub 2010 Apr 3.

3.

Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.

Madan V, Paul D, Lohmann V, Bartenschlager R.

Gastroenterology. 2014 May;146(5):1361-72.e1-9. doi: 10.1053/j.gastro.2014.01.055. Epub 2014 Jan 31.

PMID:
24486951
4.

A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.

Yang F, Robotham JM, Grise H, Frausto S, Madan V, Zayas M, Bartenschlager R, Robinson M, Greenstein AE, Nag A, Logan TM, Bienkiewicz E, Tang H.

PLoS Pathog. 2010 Sep 23;6(9):e1001118. doi: 10.1371/journal.ppat.1001118.

5.

The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A.

Waller H, Chatterji U, Gallay P, Parkinson T, Targett-Adams P.

J Virol Methods. 2010 May;165(2):202-10. doi: 10.1016/j.jviromet.2010.01.020. Epub 2010 Feb 2.

PMID:
20132841
6.

HCV NS5A and IRF9 compete for CypA binding.

Bobardt M, Hopkins S, Baugh J, Chatterji U, Hernandez F, Hiscott J, Sluder A, Lin K, Gallay PA.

J Hepatol. 2013 Jan;58(1):16-23. doi: 10.1016/j.jhep.2012.08.007. Epub 2012 Aug 15.

7.

The isomerase active site of cyclophilin A is critical for hepatitis C virus replication.

Chatterji U, Bobardt M, Selvarajah S, Yang F, Tang H, Sakamoto N, Vuagniaux G, Parkinson T, Gallay P.

J Biol Chem. 2009 Jun 19;284(25):16998-7005. doi: 10.1074/jbc.M109.007625. Epub 2009 Apr 20.

8.

Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors.

Nag A, Robotham JM, Tang H.

J Virol. 2012 Dec;86(23):12616-24. doi: 10.1128/JVI.01351-12. Epub 2012 Sep 12.

9.

Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.

Garcia-Rivera JA, Bobardt M, Chatterji U, Hopkins S, Gregory MA, Wilkinson B, Lin K, Gallay PA.

Antimicrob Agents Chemother. 2012 Oct;56(10):5113-21. doi: 10.1128/AAC.00919-12. Epub 2012 Jul 16.

10.

Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.

Chatterji U, Bobardt M, Tai A, Wood M, Gallay PA.

Antimicrob Agents Chemother. 2015 May;59(5):2496-507. doi: 10.1128/AAC.04958-14. Epub 2015 Feb 9.

11.

Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics.

Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, Zayas M, Lohmann V, Luban J, Bartenschlager R.

PLoS Pathog. 2009 Aug;5(8):e1000546. doi: 10.1371/journal.ppat.1000546. Epub 2009 Aug 14. Erratum in: PLoS Pathog. 2009 Sep;5(9). doi: 10.1371/annotation/29dffb2a-5d37-4196-b166-b0b15bc2f3fd. Lopez, Margarita Zayas [corrected to Zayas, Margarita].

12.

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, Vandamme AM, Bartenschlager R, Gallay P, Lippens G, Neyts J.

PLoS One. 2010 Oct 27;5(10):e13687. doi: 10.1371/journal.pone.0013687.

13.

Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes.

Chatterji U, Bobardt MD, Lim P, Gallay PA.

J Gen Virol. 2010 May;91(Pt 5):1189-93. doi: 10.1099/vir.0.018531-0. Epub 2010 Jan 27.

14.

Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A.

Rosnoblet C, Fritzinger B, Legrand D, Launay H, Wieruszeski JM, Lippens G, Hanoulle X.

J Biol Chem. 2012 Dec 28;287(53):44249-60. doi: 10.1074/jbc.M112.392209. Epub 2012 Nov 14.

15.

SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.

Hopkins S, Scorneaux B, Huang Z, Murray MG, Wring S, Smitley C, Harris R, Erdmann F, Fischer G, Ribeill Y.

Antimicrob Agents Chemother. 2010 Feb;54(2):660-72. doi: 10.1128/AAC.00660-09. Epub 2009 Nov 23.

16.

Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.

Yang F, Robotham JM, Nelson HB, Irsigler A, Kenworthy R, Tang H.

J Virol. 2008 Jun;82(11):5269-78. doi: 10.1128/JVI.02614-07. Epub 2008 Apr 2.

17.

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.

Gallay PA, Bobardt MD, Chatterji U, Trepanier DJ, Ure D, Ordonez C, Foster R.

PLoS One. 2015 Aug 11;10(8):e0134707. doi: 10.1371/journal.pone.0134707. eCollection 2015.

18.

Seed sequence-matched controls reveal limitations of small interfering RNA knockdown in functional and structural studies of hepatitis C virus NS5A-MOBKL1B interaction.

Chung HY, Gu M, Buehler E, MacDonald MR, Rice CM.

J Virol. 2014 Oct;88(19):11022-33. doi: 10.1128/JVI.01582-14. Epub 2014 Jul 16.

19.

Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.

Puyang X, Poulin DL, Mathy JE, Anderson LJ, Ma S, Fang Z, Zhu S, Lin K, Fujimoto R, Compton T, Wiedmann B.

Antimicrob Agents Chemother. 2010 May;54(5):1981-7. doi: 10.1128/AAC.01236-09. Epub 2010 Feb 22.

20.

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.

Chatterji U, Garcia-Rivera JA, Baugh J, Gawlik K, Wong KA, Zhong W, Brass CA, Naoumov NV, Gallay PA.

Antimicrob Agents Chemother. 2014 Jun;58(6):3327-34. doi: 10.1128/AAC.00016-14. Epub 2014 Mar 31.

Supplemental Content

Support Center